1-Imidazol-1-yl-3-methyl-4-propylpyrrolidin-2-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1-Imidazol-1-yl-3-methyl-4-propylpyrrolidin-2-one
• 英文别名: 1-imidazol-1-yl-3-methyl-4-propylpyrrolidin-2-one
• 化学式: C₁₁H₁₇N₃O
• 分子量: 207.27
• InChiKey: NQANEUXZYUFANQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  38.1
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION
  申请人：Agenebio, Inc.

  公开号：EP2968220A1

  公开（公告）日：2016-01-20
• METHODS AND COMPOSITONS FOR IMPROVING COGNITIVE FUNCTION
  申请人：The Johns Hopkins University

  公开号：EP2968257A1

  公开（公告）日：2016-01-20
• [EN] METHODS AND COMPOSITONS FOR IMPROVING COGNITIVE FUNCTION<br/>[FR] PROCÉDÉS ET COMPOSITIONS POUR AMÉLIORER LA FONCTION COGNITIVE
  申请人：UNIV JOHNS HOPKINS

  公开号：WO2014144546A1

  公开（公告）日：2014-09-18

  This invention relates to methods and compositions for treating cognitive impairment associated with central nervous system (CNS) disorders. In particular, it relates to the use of inhibitors of synaptic vesicle glycoprotein 2A (SV2A) in combination with memantine or a derivative or an analog thereof, in treating cognitive impairment associated with central nervous system (CNS) disorders in a subject in need or at risk thereof, including, without limitation, subjects having or at risk for age-related cognitive impairment, Mild Cognitive Impairment (MCI), amnestic MCI (aMCI), Age- Associated Memory Impairment (AAMI), Age Related Cognitive Decline (ARCD), dementia, Alzheimer's Disease(AD), prodromal AD, post traumatic stress disorder (PTSD), schizophrenia or bipolar disorder, amyotrophic lateral sclerosis, cancer-therapy-related cognitive impairment, mental retardation, Parkinson's disease (PD), autism, compulsive behavior, and substance addiction.
• [EN] METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION<br/>[FR] PROCÉDÉS ET COMPOSITIONS POUR AMÉLIORER LA FONCTION COGNITIVE
  申请人：AGENEBIO INC

  公开号：WO2014144801A1

  公开（公告）日：2014-09-18

  The invention relates to compositions comprising a synaptic vesicle glycoprotein 2A (SV2A) inhibitor in an extended release and an acetylcholinesterase inhibitor (AChEIs). The invention also relates to using such compositions in treating cognitive impairment associated with central nervous system disorders in a subject in need or at risk thereof, including, without limitation, subjects having or at risk for age-related cognitive impairment, Mild Cognitive Impairment (MCI), dementia, Alzheimer's Disease(AD), prodromal AD, post traumatic stress disorder (PTSD), schizophrenia, bipolar disorder, amyotrophic lateral sclerosis (ALS), cancer-therapy-related cognitive impairment, mental retardation, Parkinson's disease (PD), autism, compulsive behavior, and substance addiction.